-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

5142 Multimodal Mobile Application to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant (HCT) Survivors

Program: Oral and Poster Abstracts
Session: 905. Outcomes Research—Lymphoid Malignancies: Poster III
Hematology Disease Topics & Pathways:
Research, adult, Clinical Research, patient-reported outcomes, survivorship, Study Population, Human
Monday, December 11, 2023, 6:00 PM-8:00 PM

Areej El-Jawahri, MD1, Jennifer Reese, PhD2*, Lara Traeger3*, Don Dizon, MD4*, Sharon Bober5*, Julie Vanderklish, ANP3*, Richard Newcomb3*, Zachariah Defilipp, MD6, Yi-Bin Chen, MD, MS3 and Jennifer Temel3*

1Massachusetts General Hospital, Allston, MA
2Fox Chase Cancer Center, Philadelphia, PA
3Massachusetts General Hospital, Boston, MA
4Lifespan Cancer Institute, Providence, RI
5Dana Farber Cancer Institute, Boston, MA
6Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA

Background: Sexual dysfunction is the most common complication affecting HCT survivors and is associated with worse patient-reported quality of life (QOL) and psychological distress. Yet, interventions to address sexual dysfunction in HCT survivors are lacking.

Methods: We conducted a pilot randomized trial of a multimodal mobile application (SHIFT) to address sexual dysfunction for patients with hematologic malignancies who were at least 3 months post autologous or allogeneic HCT and endorsed sexual dysfunction causing distress. Patients were randomly assigned to SHIFT or enhanced usual care. Intervention participants met with a trained HCT clinician for a brief clinical exam to address biological causes of sexual dysfunction and were then provided access to SHIFT for 8 weeks. SHIFT consists of five modules focused on educating and empowering patients to address their sexual health concerns and addressing the biologic, interpersonal, social, and psychological causes of sexual dysfunction. Patients assigned to enhanced usual care met with the trained HCT clinician for a brief clinical exam and they were not given access to SHIFT. The primary endpoint was feasibility, defined a priori as at least 60% of eligible patients enrolling and 60% of those enrolled completing at least 70% of the SHIFT modules. We assessed patient global satisfaction with sex, interest in sex, orgasm pleasure (PROMIS), QOL (Functional Assessment of Cancer Therapy-Bone Marrow Transplant [FACT-BMT]), and psychological distress (Hospital Anxiety and Depression-Scale [HADS]) at baseline and 8 weeks. To assess the usability of SHIFT, we used the System Usability Scale (>80 indicates excellent usability). We a priori identified a p-value <0.25 as promising for preliminary efficacy in this pilot study.

Results: We enrolled 64.2% (61/95) of eligible patients (mean age = 57.2 (SD=14.2), 60% male). In the intervention group, 70.0% completed ≥ 80% of the SHIFT modules, and 66.7% completed all SHIFT modules. Patients assigned to SHIFT used the app for a mean of 155 minutes (Range: 38.1 – 394.9). At 8 weeks, patients randomized to SHIFT reported improved satisfaction with sex (14.6 vs. 12.3, P=0.076), interest in sex (6.7 vs. 5.7, P=0.040), and orgasm pleasure (9.7 vs. 8.2, P=0.106), compared to those assigned to enhanced usual care. SHIFT participants also reported better QOL (115.6 vs. 108.3, P=0.039), anxiety (4.6 vs. 6.4, P=0.043), and depression symptoms (3.6 vs. 5.4, P=0.016) compared to those assigned to enhanced usual care. The SHIFT mean usability score was 80.5 (SD=13.6).

Conclusions: A multimodal mobile app to address sexual dysfunction is feasible to use for HCT survivors and has promising preliminary efficacy for improving sexual health outcomes, QOL, and psychological distress. A future multi-site trial is needed to assess the efficacy of SHIFT for improving sexual function and QOL in HCT survivors.

Disclosures: El-Jawahri: GSK: Consultancy; Incyte Corporation: Consultancy; Novartis: Consultancy. Defilipp: Taiho Oncology: Research Funding; Sanofi: Consultancy; Incyte: Consultancy, Research Funding; Regimmune: Research Funding; MorphoSys: Consultancy; Inhibrx: Consultancy; PharmaBiome AG: Consultancy; Ono Pharmaceutical: Consultancy.

*signifies non-member of ASH